Company / Revenue
Kymera Therapeutics, Inc. Revenue History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$39.2M
FY2025
5-year range
$2.9M / $78.6M
FY2021-FY2025
Trend
-16.7%
vs FY2024
Sector context
#124 of 155
Health Care
What the data says
Kymera Therapeutics, Inc.'s revenue of $39M is lower than 80% of companies in the Health Care sector (FY2025). Declined from $79M to $39M over the past 2 years.
Based on SEC 10-K filings.
$39M in FY2025 with a 5-year CAGR of +68.0%.
Declined from $79M to $39M over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- -5.7%
- 5-Year CAGR
- +68.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 20% in Health CareTop 80% of 155This company $39.2M Sector average $4.5B
▼
-99.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +68.0%, indicating consistent growth.
- In FY2025, revenue decreased 16.7% year-over-year.
- Ranks #124 out of 155 companies in the Health Care sector.
- Peak revenue was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 3.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $39.2M | -16.7% |
| FY2024 | $47.1M | -40.1% |
| FY2023 | $78.6M | +67.8% |
| FY2022 | $46.8M | +1496.0% |
| FY2021 | $2.9M | +0.0% |
| FY2020 | $2.9M | +0.0% |
| FY2019 | $2.9M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 30, 2026